Submission Details
| 510(k) Number | K140105 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 15, 2014 |
| Decision Date | March 18, 2014 |
| Days to Decision | 62 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Statement |
K140105 is an FDA 510(k) clearance for the HEVYLITE HUMAN IGA KAPPA KIT FOR USE ON SIEMENS BNII, HEVYLITE HUMAN IGA LAMBDA KIT FOR USE ON SIEMENS BNII, a Immunoglobulin A Kappa Heavy & Light Chain Combined (Class II — Special Controls, product code OPX), submitted by The Binding Site (Birmingham, GB). The FDA issued a Cleared decision on March 18, 2014, 62 days after receiving the submission on January 15, 2014. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5510.
| 510(k) Number | K140105 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 15, 2014 |
| Decision Date | March 18, 2014 |
| Days to Decision | 62 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Statement |
| Product Code | OPX — Immunoglobulin A Kappa Heavy & Light Chain Combined |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.5510 |
| Definition | Intended For The In-vitro Quantification Of Iga Kappa Concentration In Human Serum. The Result Is To Be Used With Previously Diagnosed Iga Multiple Myeloma, In Conjunction With Other Clinical And Laboratory Findings. For Previously Diagnosed Iga Multiple Myeloma Patients. |